Wearable Core Body Temperature Monitoring for Early Detection of Cytokine Release Syndrome in Outpatients Receiving CAR T-Cell Therapy
A Randomized Controlled Trial of a Wearable Core Body Temperature Sensor Versus Standard Temperature Monitoring for Early Detection of Cytokine Release Syndrome in Patients Undergoing CAR T-Cell Therapy in an Outpatient Setting
The purpose of this research study is to see if a wearable temperature monitoring patch can detect cytokine release syndrome earlier than traditional oral temperature monitoring.
研究概览
详细说明
This randomized pilot study is designed to evaluate the efficacy of a continuous temperature-monitoring wearable patch in patients receiving CAR-T therapy in the outpatient setting, comparing its performance to standard institutional monitoring protocols.
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习联系方式
- 姓名:Courtney Schepel
- 电话号码:(980) 442-2327
- 邮箱:Courtney.Schepel@advocatehealth.org
研究联系人备份
- 姓名:Cindy Varga, MD
- 电话号码:704-355-2000
- 邮箱:Cindy.Varga@advocatehealth.org
学习地点
-
-
North Carolina
-
Charlotte、North Carolina、美国、28204
- Atrium Health Levine Cancer
-
首席研究员:
- Cindy Varga, MD
-
接触:
- Courtney Schepel
- 电话号码:980-442-2327
- 邮箱:Courtney.Schepel@advocatehealth.org
-
Winston-Salem、North Carolina、美国、27103
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center
-
接触:
- John McKay, DO
- 邮箱:John.Mckay@wfusm.edu
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
Patients:
- Ability to understand and willingness to sign an IRB-approved informed consent
- Age ≥ 18 years at the time of consent
- Scheduled to undergo CAR-T therapy in the outpatient setting at AHWFBCCC
- Ability to read and understand the English and/or Spanish language
- As determined by the enrolling investigator, ability of the participant to understand and comply with study procedures for the entire length of the study
- Access to a mobile device for the duration of the trial
Provider/Staff:
Provider/staff participants must meet all of the following inclusion criteria to participate in the study:
- Verbally agree to participate
- Hospital at Home outpatient provider/advanced practice provider/nurse of at least one patient participant enrolled on Arm A who completed 14 days of temperature monitoring
Exclusion Criteria:
Patients:
- Planned prophylactic tocilizumab for mitigation of CRS as documented in the clinical trials pathway submission
- History of silicone allergy
- History of Medical Adhesive-Related Skin Injury (MARSI)
- Known skin condition that might preclude safe application of the patch, in the opinion of the enrolling investigator
Provider/Staff:
None
学习计划
研究是如何设计的?
设计细节
- 主要用途:支持治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
其他:Arm A: TempShield Continuous Temperature Monitoring plus SOC Temperature Monitoring
Standard of care oral temperature monitoring plus TempShield continuous temperature monitoring patch |
Patient participants will receive instruction from a research designee regarding use of the TempShield patch and smartphone application for continuous at-home temperature monitoring. Patient participants will complete onboarding of the application on their smartphone with assistance from the research designee, if necessary. Patient participants should place the patch immediately after completion of CAR-T infusion in the outpatient setting, with assistance from the research designee. |
|
其他:Arm B: SOC Temperature Monitoring
Standard of care oral temperature monitoring |
Standard of care oral temperature monitoring |
|
无干预:Arm C: Provider/Staff
Providers/staff are Hospital at Home personnel who support patients undergoing outpatient CAR-T therapy and who have monitored at least one participant enrolled on Arm A of the study. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Time to first recorded temperature elevation indicative of Cytokine Release Syndrome (CRS)
大体时间:From the initiation of CAR-T infusion up to Day 14 post-infusion.
|
Time (in hours) from the initiation of CAR-T infusion to the first occurrence of a recorded body temperature elevation of ≥ 100.4°F (38.0°C) during the 14-day post-CAR-T observation period. Participants who do not experience this defined temperature elevation within the 14 days will be censored at the time of their last recorded temperature reading during this window. Reported by arm. |
From the initiation of CAR-T infusion up to Day 14 post-infusion.
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Incidence of temperature elevation indicative of Cytokine Release Syndrome (CRS)
大体时间:From the initiation of CAR-T infusion up to Day 14 post-infusion.
|
Number of participants who experience at least one recorded body temperature elevation of ≥ 100.4°F (38.0°C) during the 14-day post-CAR-T observation period. Reported by arm. |
From the initiation of CAR-T infusion up to Day 14 post-infusion.
|
|
Incidence of high-grade (grade 2 or higher) Cytokine Release Syndrome (CRS)
大体时间:From the initiation of CAR-T infusion up to Day 14 post-infusion.
|
Number of participants who experience grade 2 or higher CRS during the 14-day post-CAR-T observation period. Reported by arm. |
From the initiation of CAR-T infusion up to Day 14 post-infusion.
|
|
Time to resolution of Cytokine Release Syndrome (CRS) from temper elevation indicative of CRS (temperature ≥ 100.4 °F)
大体时间:From the temperature elevation (≥ 100.4 °F) to resolution during the 14 days after CAR-T infusion.
|
Time (in hours) from the from onset of fever indicative of CRS (temperature ≥ 100.4 °F) during the 14-day post-CAR-T observation period to resolution (i.e., when the participant no longer meets the CRS diagnostic criteria). If a participant experiences multiple episodes of CRS during the 14-day post-CAR-T observation period, the duration can be calculated per episode and cumulatively. This will be calculated for participants experiencing CRS (temperature ≥ 100.4 °F) during the 14-day post-CAR-T observation period. Reported by arm. |
From the temperature elevation (≥ 100.4 °F) to resolution during the 14 days after CAR-T infusion.
|
|
Time to intervention after fever detection (temperature ≥ 100.4 °F)
大体时间:From the temperature elevation (≥ 100.4 °F) to intervention during the 14 days after CAR-T infusion.
|
Time (in hours) from documented temperature elevation of ≥ 100.4° F to clinician intervention (e.g., supportive care, medication followed by observation, etc.). This will be calculated for participants experiencing CRS during the 14-day post-CAR-T observation period. Reported by arm. |
From the temperature elevation (≥ 100.4 °F) to intervention during the 14 days after CAR-T infusion.
|
|
Incidence of admission to the Intensive Care Unit (ICU) due to temperature elevation indicative of CRS
大体时间:From the initiation of CAR-T infusion up to Day 14 post-infusion.
|
Number of participants admitted to the ICU due to temperature elevation indicative of CRS during the 14-day post-CAR-T observation period. Reported by arm. |
From the initiation of CAR-T infusion up to Day 14 post-infusion.
|
|
Time to discharge after admission to the Intensive Care Unit (ICU)
大体时间:From the initiation of CAR-T infusion up to Day 14 post-infusion.
|
Time (in hours) from ICU admission to ICU discharge. If a participant has multiple ICU admissions during the 14-day post-CAR-T observation period, the duration will be calculated cumulatively. Reported by arm. |
From the initiation of CAR-T infusion up to Day 14 post-infusion.
|
|
Length of hospital stay
大体时间:From the initiation of CAR-T infusion up to Day 14 post-infusion.
|
Number of inpatient nights from hospital admission to hospital discharge due to temperature elevation indicative of CRS during the 14-day post-CAR-T observation period. If a participant has multiple hospital admissions due to CRS during the 14-day post-CAR-T observation period, the duration reported will be cumulative across all stays. This endpoint will be calculated for participants admitted to this hospital during the 14-day post-CAR-T observation period due to temperature elevation indicative of CRS. Reported by arm. |
From the initiation of CAR-T infusion up to Day 14 post-infusion.
|
|
Incidence of Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)
大体时间:From the initiation of CAR-T infusion up to Day 14 post-infusion.
|
Number of participants experiencing ICANS during the 14-day post-CAR-T observation period. Reported by arm. |
From the initiation of CAR-T infusion up to Day 14 post-infusion.
|
|
Largest change in body temperature from baseline recorded during the 14-day post-CAR-T observation period
大体时间:From the initiation of CAR-T infusion up to Day 14 post-infusion.
|
The maximum numerical difference in body temperature recorded from baseline during the 14-day post-CAR-T observation period. Reported by arm. |
From the initiation of CAR-T infusion up to Day 14 post-infusion.
|
|
The proportion of hours during the 14-day post CAR-T observation period when patch was worn
大体时间:From the initiation of CAR-T infusion up to Day 14 post-infusion.
|
The proportion of hours during the 14-day post-CAR-T observation period in which at least one valid human body temperature reading (86 °F to 108 °F) was recorded by the wearable patch, defined as Total adherence = (Number of hours with at least one valid temperature reading)/(24*14 hours). This will be calculated for participants randomized to wear the remote temperature monitoring device. |
From the initiation of CAR-T infusion up to Day 14 post-infusion.
|
|
The proportion of paired temperature readings from the temperature patch and an oral thermometer within one degree Fahrenheit in a five-minute window during the 14-day post-CAR-T observation period
大体时间:From the initiation of CAR-T infusion up to Day 14 post-infusion.
|
The number 5-minute intervals in the 14-day post-CAR-T observation period (from the first patch reading indicating a temperature from 86 °F to 108 °F), when concordance between the temperature patch and an oral thermometer within one degree Fahrenheit was observed. |
From the initiation of CAR-T infusion up to Day 14 post-infusion.
|
|
Patient satisfaction with CAR-T temperature monitoring methods
大体时间:The Day 14 post-infusion (+28 days) study calendar visit.
|
Patient satisfaction as assessed by the study survey, evaluating satisfaction on a Likert scale where higher scores indicate a higher level of patient satisfaction with the assigned monitoring method (standard of care vs. wearable patch). |
The Day 14 post-infusion (+28 days) study calendar visit.
|
合作者和调查者
调查人员
- 首席研究员:Cindy Varga, MD、Wake Forest University Health Sciences
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- IRB00158734
- ONC-MM-2501 (其他标识符:Atrium Health Wake Forest Baptist Comprehensive Cancer Center)
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
在美国制造并从美国出口的产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.